scholarly journals Nivolumab Effective for Gastric and Lung Cancers but Not for Multiple Myeloma in a Multiple Primary Cancer Patient

2021 ◽  
Vol 2021 ◽  
pp. 1-4
Author(s):  
Tsukasa Yasuda ◽  
Junji Hiraga ◽  
Michihiko Narita ◽  
Yoshimasa Tanikawa ◽  
Tomoyuki Tsuzuki
Keyword(s):  
Multiple Myeloma ◽  
Primary Lung Cancer ◽  
Multiple Primary Cancers ◽  
Upper Gastrointestinal Endoscopy ◽  
Multiple Primary Cancer ◽  
Lung Cancers ◽  
Multiple Primary ◽  
Third Line Therapy ◽  
Third Line ◽  
Upper Gastrointestinal

The case of a 76-year-old man with multiple primary cancers that were treated with nivolumab is presented. Six years earlier, he was diagnosed with multiple myeloma (MM) and was treated with several chemotherapies. He was also diagnosed with gastric cancer with liver metastasis and primary lung cancer by upper gastrointestinal endoscopy and computed tomography (CT). Nivolumab treatment was given as third-line therapy, and it was effective for gastric and lung cancers. But MM worsened, and the patient died. There is no standard treatment for multiple primary cancers, and the development of effective treatments for multiple primary cancers is important.

scholarly journals Upper Gastrointestinal Endoscopy Detection of Synchronous Multiple Primary Cancers in Esophagus and Stomach: Single Center Experience from China

2012 ◽  
Vol 2012 ◽  
pp. 1-4 ◽  
Author(s):  
Rui Wang ◽  
Mo-Jin Wang ◽  
Jin-Lin Yang ◽  
Cheng-Wei Tang
Keyword(s):  
Squamous Cell ◽  
Endoscopic Examination ◽  
Clinicopathological Features ◽  
Multiple Primary Cancers ◽  
Upper Gastrointestinal Endoscopy ◽  
Simultaneous Exposure ◽  
Single Center Experience ◽  
Multiple Primary ◽  
History Of ◽  
Upper Gastrointestinal

The present study was undertaken to clarify the prevalence and clinicopathological features of synchronous multiple primary cancers (SMPCs) under upper gastrointestinal endoscopic examination. We enrolled 45,032 consecutive patients who underwent upper gastrointestinal endoscopic examination for digestive disease from January 2006 to December 2007 in our hospital and analyzed the clinicopathological features of SMPCs in esophagus and stomach. SMPCs are defined as two or over two different cancerous lesions developing in the same or other organs within 6 months. SMPCs were identified in 46 patients (0.1%). The gender ratio was 5.6 : 1 (male/female) and the mean age was 59.4 years. Synchronous esophageal and gastric cancers were the most frequent, being seen in 32 patients (0.07%). The most common histological types of SMPCs were squamous cell carcinoma in esophagus and adenocarcinoma in stomach, respectively. There were 27 (59%) SMPCs patients who had the history of simultaneous exposure to tobacco smoking and alcohol drinking. Additionally, 32 (78%) esophageal squamous cell cancers were associated with tobacco use. And 23 adenocarcinomas of the stomach were associated withHelicobacter pyloriinfection.

scholarly journals Preoperative virtual simulation for synchronous multiple primary lung cancers using three-dimensional computed tomography lung reconstruction: a case report

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Weichun Wu ◽  
Yimin Wu ◽  
Gang Shen ◽  
Guofei Zhang
Keyword(s):  
Computed Tomography ◽  
Thoracoscopic Surgery ◽  
Three Dimensional ◽  
Primary Lung Cancer ◽  
Pulmonary Nodules ◽  
Term Survival ◽  
Lung Cancers ◽  
Multiple Primary ◽  
Feasible Alternative

Abstract Background As the positions and sizes of nodules in synchronous multiple primary lung cancer (SMPLC) patients differ, the development of surgical strategies to maximize long-term survival and preserved postoperative pulmonary function in SMPLC patients for whom surgical resection is an alternative strategy presents challenges. Case presentation We provide a case managed through video-assisted thoracoscopic surgery (VATS) resection using three-dimensional computed tomography lung reconstruction (3D-CTLR) to reconstruct lobes containing pulmonary nodules to preoperatively simulate and intraoperatively guide the extent and method of resection. Conclusion The successful attempt demonstrates a technically simplified, feasible alternative to preoperative plans utilizing less invasive VATS to manage SMPLC.

Four cases of simultaneous triple primary cancers of the hypopharynx, esophagus, and stomach

2005 ◽  
Vol 132 (5) ◽  
pp. 788-793 ◽  
Author(s):  
Yoichi Ikeda ◽  
Mamoru Tsukuda ◽  
Junichi Ishitoya ◽  
Yasuhiro Arai ◽  
Hideki Matsuda ◽  
...  
Keyword(s):  
Treatment Modality ◽  
Argon Plasma Coagulation ◽  
Argon Plasma ◽  
Hypopharyngeal Cancer ◽  
Multiple Primary Cancers ◽  
Multiple Primary Cancer ◽  
Retrospective Case ◽  
Gastric Carcinomas ◽  
Multiple Primary ◽  
Retrospective Case Study

OBJECTIVE: To study the efficacy of intensive chemotherapy for simultaneous triple primary cancers of the hypopharynx, esophagus, and stomach. STUDY DESIGN: Retrospective case study. METHODS: From April 2000 to March 2002, we treated 4 patients who had simultaneous triple primary cancers, including hypopharyngeal, esophageal, and gastric carcinomas. These 4 patients were designated as the objects for analysis, and the treatment modality for simultaneous multiple primary cancer cases was examined. RESULTS: In 3 of 4 patients, all 3 primary cancers could be controlled by intensive induction chemotherapy and concurrent chemoradiotherapy for hypopharyngeal cancer and by endoscopic mucosal resection or argon plasma coagulation for esophageal and gastric carcinomas. CONCLUSIONS: In the treatment modality for simultaneous multiple primary cancers, including head and neck cancer, it is important to select intensive systemic chemotherapy and decide the order for treating each primary lesion in consideration of each patient's curability and prognosis. (Otolaryngol Head Neck Surg 2005;132:788-93.)

Compassionate Use of Combined Anti-Inflammatory and Angiostatic Treatment as Third-Line Therapy in Eight Patients with Multiple Myeloma – a Combined Treatment Setting of Lenalidomide with Pioglitazone, Dexamethasone and Low-Dose Treosulfan.

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 4958-4958
Author(s):  
Albrecht Reichle ◽  
Martin Vogelhuber ◽  
Ernst Holler ◽  
Joachim Hahn ◽  
Reinhard Andreesen
Keyword(s):  
Multiple Myeloma ◽  
Combined Treatment ◽  
Cytotoxic Agents ◽  
Treatment Setting ◽  
Compassionate Use ◽  
Line Therapy ◽  
Third Line Therapy ◽  
Anti Inflammatory ◽  
Third Line ◽  
Dose Levels

Abstract Abstract 4958 Introduction Therapeutic options for patients with refractory and multifold pretreated multiple myeloma (MM) are limited, as patients have already received the novel targeted therapy approaches at this stage. Continuous production and release of pro-inflammatory cytokines may account for its resistance towards cytotoxic agents. Therefore, a multi-targeted approach consisting of anti-angiogenic, anti-inflammatory and anti-tumor components was implemented for response induction prior to and after allogeneic transplantation. Methods Within a compassionate-use program eight patients suffering from refractory or relapsed osteolytic multiple myeloma (MM) or plasma cell leukemia (PCL) and proven progression of serum paraprotein levels were treated in third-line continuously with daily lenalidomide 10 mg, pioglitazone 60 mg, treosulfan 250 mg once daily, and dexamethasone 1 mg. Results Here we report results of eight patients (48 to 63 years old) treated for refractory (n= 7) or relapsed (n= 1) multiple myeloma (n= 7) or PCL (n= 1). Prior therapy consisted of double autologous transplantation with high-dose treosulfan/melphalan conditioning, lenalidomide and/or bortezomib. One patient suffered from progressive disease following allogeneic stem cell transplantation (allo-SCT). No side effects > WHO 2 occurred on treatment. In one patient, bortezomib-induced motoric polyneuropathia partially resolved on study medication. Biomodulatory therapy induced clinically meaningful and very rapid responses, stable disease, n= 2, partial remission (PR), n= 3, and very good PR (VPR, n= 3). Therapy-induced PR and VPR facilitated allo-SCT in 2 refractory patients. A third patient with refractory disease after allo-SCT received donor lymphocytes. Two patients with allo-SCT survived in VPR for 10+ and 3+ months, respectively. One patient remained in ongoing VPR since 9 months after donor lymphocyte infusion. Patients not proceeding to allo-SCT had SD for 3 (PLC) and 4 months, VPR and PR for 3+, 4+ and 5+ months. Conclusions Together, biomodulatory therapy has remarkable clinical activity in pretreated and refractory patients with MM. The eight cases show comparatively high efficacy at low toxicity rates of a biomodulatory acting therapy approach: Although the substances have limited or no efficacy at the respective dose levels, and were already administered previously at higher dose-levels (i.e. treosulfan and/or lenalidomide), the combined treatment setting is promising since it targets the myeloma cells itself as well as the surrounding stroma. Therefore, this treatment schedule deserves further investigation and discharges now in a novel multi-center phase II trial for third-line therapy in multiple myeloma. Disclosures No relevant conflicts of interest to declare.

Analysis of Second-Line Lenalidomide Following Initial Relapse in the MM-015 Trial

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 944-944 ◽  
Author(s):  
Meletios A Dimopoulos ◽  
Maria Teresa Petrucci ◽  
Robin Foa ◽  
John V. Catalano ◽  
Martin Kropff ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Board Of Directors ◽  
Second Line ◽  
Employment Equity ◽  
Advisory Committees ◽  
Line Therapy ◽  
Third Line Therapy ◽  
Equity Ownership ◽  
Third Line ◽  
Grade 3

Abstract Abstract 944 Background: MM-009/010 established lenalidomide (LEN) + dexamethasone (DEX) as a standard of care in the treatment (Tx) of relapsed/refractory multiple myeloma (RRMM; Dimopoulos, NEJM. 2007; Weber, NEJM. 2007). The greatest benefits were observed when LEN + DEX was used at first relapse (Stadtmauer, Eur J Haematol. 2009). MM-015 is a pivotal, double-blind, randomized, placebo-controlled phase 3 trial comparing the efficacy and safety of melphalan-prednisone-lenalidomide followed by lenalidomide maintenance (MPR-R) with fixed-cycle melphalan-prednisone (MP) and melphalan-prednisone-LEN (MPR) in elderly patients (pts) with newly diagnosed multiple myeloma (NDMM) ineligible for autologous stem-cell transplant. The final analysis demonstrated unprecedented improvement in progression-free survival (PFS) in pts receiving MPR-R vs MP (31 vs 13 months [mos]; P < 0.001) with manageable toxicity (Palumbo, NEJM. 2012). The aim of this post-hoc analysis was to assess post-progression outcomes by second-line Tx and by initial MM-015 Tx arm (MPR-R, MPR, and MP). Methods: Induction and maintenance Tx has been described (Palumbo, NEJM. 2012). Pts with progressive disease during MM-015 could enroll in an open-label extension phase (OLEP) to receive LEN 25 mg (D1-21) ± DEX 40 mg (D1-4, 9–12, and 17–20) or could receive any other anti-myeloma Tx outside of the protocol. This analysis includes data up to Apr 10, 2012 (median follow-up: 48 mos after initial randomization). Time to progression (TTP) was assessed from randomization to disease progression as assessed by investigator. Time from start of second line to start of third-line Tx was assessed as a surrogate for TTP in second line. Safety data were assessed only for pts enrolled in the OLEP. Results: A total of 459 pts were enrolled in MM-015. Consistent with the superior PFS of MPR-R, fewer pts from the MPR-R arm progressed compared with the MPR and MP arms: 54% (81/150) vs 77% (117/152), and 83% (127/153) respectively. Compared with the overall population, pts receiving second-line Tx had shorter median first-line TTP (29 vs 20 mos), particularly for the MPR-R arm. This suggests that the present subset of pts in the MPR-R arm who started second-line therapy represents the early progressors, those with worse prognosis or more aggressive disease (Table). More pts received second-line Tx in the MP (72%) and MPR (58%) arms vs MPR-R arm (30%, Table); second-line Tx type was heterogeneous for MPR-R pts. Median time from second- to third-line Tx was significantly longer for LEN-based Tx vs non-LEN-based Tx across the 3 arms: MPR-R (18 vs 13 mos; P = 0.044), MPR (23 vs 8 mos; P = 0.02), and MP (18 vs 10 mos; P = 0.001). Median time from second- to third-line therapy with bortezomib (BORT)-based regimens was 14, 16, and 12 mos, respectively. This corresponded to higher proportions of pts remaining on second-line LEN at 2 yrs (38%, 44%, and 40%) vs non-LEN (15%, 30%, and 13%) for MPR-R, MPR, and MP, respectively. When evaluating second-line BORT, 22%, 33%, and 17%, respectively, had not progressed from second- to third-line therapy at 2 years. Prior LEN maintenance did not appear to induce resistant relapses as time from second- to third-line Tx was similar for all arms (Table) and all comparisons: MPR-R vs MP (hazard ratio [HR] = 0.924; P = 0.69), MPR-R vs MPR (HR = 1.076; P = 0.71), and MPR vs MP (HR = 0.895; P = 0.53). With limited follow-up, no significant differences in post-relapse OS have been detected. Newly occurring grade 3/4 adverse events (AEs) reported for ≥ 5% of pts entering the OLEP (n = 153) were neutropenia (11%) and anemia (5%). Grade 3/4 deep vein thrombosis and peripheral neuropathy occurred in 3% and 1% of pts, respectively. Conclusions: LEN-based Tx was active in the second line, with comparable efficacy regardless of first-line therapy (MPR-R, MPR, or MP). Although pt numbers are relatively small, and this is a non-randomized comparison, results with second-line LEN-based therapy compared favorably to outcomes with other Tx. The OLEP tolerability profile was favorable, with limited newly occurring grade 3/4 AEs. Importantly, LEN maintenance does not appear to induce resistant relapses. These results support the known activity of LEN as second-line MM therapy. Disclosures: Dimopoulos: Celgene Corp: Honoraria. Off Label Use: Lenalidomide as frontline treatment of multiple myeloma. Petrucci:Celgene Corp: Honoraria. Foa:Celgene Corp: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Catalano:Celgene Corp: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Yu:Celgene Corp: Employment, Equity Ownership. Herbein:Celgene Corp: Employment, Equity Ownership. Jacques:Celgene Corp: Employment, Equity Ownership. Palumbo:Celgene Corp: Honoraria, Membership on an entity's Board of Directors or advisory committees.

scholarly journals Multiple primary cancer with primary lung cancer in 986 autopsy cases.

Haigan ◽  
1986 ◽  
Vol 26 (7) ◽  
pp. 779-788
Author(s):  
Yasuki Fukuda ◽  
Masayuki Nakata ◽  
Shuuichi Yoneda ◽  
Yukio Noguchi ◽  
Takeshi Homma ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Primary Lung Cancer ◽  
Multiple Primary Cancer ◽  
Primary Cancer ◽  
Multiple Primary

scholarly journals Comparison of Clinicopathological Characteristics Between the Anterior and Posterior Type of Squamous Cell Carcinoma of the Floor of the Mouth: The Anterior Type Is a Risk Factor for Multiple Primary Cancer

2021 ◽  
Vol 11 ◽  
Author(s):  
Yu Oikawa ◽  
Kae Tanaka ◽  
Toshimitsu Ohsako ◽  
Takuma Kugimoto ◽  
Takeshi Kuroshima ◽  
...  
Keyword(s):  
Overall Survival ◽  
Squamous Cell Carcinoma ◽  
Risk Factor ◽  
Survival Rates ◽  
Clinicopathological Characteristics ◽  
Multiple Primary Cancers ◽  
Multiple Primary Cancer ◽  
Primary Cancer ◽  
Floor Of The Mouth ◽  
Multiple Primary

BackgroundFloor of the mouth (FOM) squamous cell carcinoma (SCC) accounts for approximately 10% of all oral SCCs. FOM SCC can be classified into the anterior and posterior types according to their site of origin, but few studies have compared these types. This study sought to clarify differences in clinicopathological characteristics between these two types.MethodsA total of 1,220 patients with oral SCC were treated at our department from January 2001 to December 2015. Among these patients, 62 had FOM SCC. The FOM SCCs were classified into two groups: the anterior type and the posterior type. The anterior and posterior types were defined by the boundary connecting the spaces between the canine and the first premolar bilaterally. We retrospectively compared the sex, age, smoking and drinking history, clinical stage, treatment, histopathological diagnosis, multiple primary cancers, and outcomes of the two groups.ResultsAmong the 62 patients, 32 had the anterior type, while 30 had the posterior type. The anterior type was found more significantly in men (p = 0.01) and individuals with a smoking history than the posterior type (p = 0.04). pN2–3 cervical lymph node metastasis was significantly more common in the anterior type than in the posterior type (p = 0.01). The median depth of invasion in the anterior type was 4 mm. Multivariate analysis showed that the anterior type was an independent risk factor for multiple primary cancer development in FOM SCC (p = 0.02). The cumulative 10-year disease-specific survival rates of the anterior and posterior types were 92.8 and 95.0%, respectively, while the overall survival rates were 65.4 and 95.0%, respectively. In the anterior type FOM SCC, a lower overall survival rate was associated with multiple primary cancers and smoking-related diseases.ConclusionSmoking cessation and adequate systemic screening for multiple primary cancers are needed to improve the prognosis of FOM SCC, particularly the anterior type.

scholarly journals Multiple Primary Lung Cancer Comprised of Adenocarcinoma and Adenoid Cystic Carcinoma: A Case Report

2021 ◽  
Author(s):  
jieyu xu ◽  
Xiaorong Yang
Keyword(s):  
Lung Cancer ◽  
Adenoid Cystic Carcinoma ◽  
Primary Lung Cancer ◽  
Symptomatic Treatment ◽  
Rare Type ◽  
Radiographic Findings ◽  
Lung Cancers ◽  
Adenoid Cystic ◽  
First Choice ◽  
Multiple Primary

Abstract Background: Multiple primary lung cancer is a rare type of tumor, which is necessary to differentiate from a metastatic tumor.Case presentation: We report a 67-year-old female with coughing and expectoration in the past eight days. Chest computed tomography revealed that there are two nodules in the patient's lung. Radiographic findings cannot distinguish between the two nodules and distinguish between primary and metastatic lesions.The patient underwent bronchoscopic biopsy and percutaneous lung puncture. Combined with morphological and immunohistochemical results, we concluded that this is a case of multiple primary lung cancers, consisting of adenocarcinoma and adenoid cystic carcinoma. In clinical practice, surgery is considered to be the first choice for the treatment of cases of multiple primary lung cancer. The patient received symptomatic treatment because of the metastases. Conclusions: The article aims to report a rare case and emphasize the role of immunohistochemistry in diagnosing multiple lung cancer.

scholarly journals EP1.16-21 Frequencies and Prognosis of Non-Small Cell Lung Cancers Complicated with Synchronous/Metachronous Multiple Primary Cancers

2019 ◽  
Vol 14 (10) ◽  
pp. S1072-S1073
Author(s):  
T. Honda ◽  
R. Ochiai ◽  
T. Haruyama ◽  
M. Ishihara ◽  
T. Sakamoto ◽  
...  
Keyword(s):  
Small Cell ◽  
Multiple Primary Cancers ◽  
Small Cell Lung ◽  
Lung Cancers ◽  
Multiple Primary

ABO and Rho(D) blood types in patients with multiple primary cancers

JAMA ◽  
1966 ◽  
Vol 198 (12) ◽  
pp. 1297-1298 ◽  
Author(s):  
K. E. Holley
Keyword(s):  
Multiple Primary Cancers ◽  
Blood Types ◽  
Multiple Primary
Sign in / Sign up

Export Citation Format

Share Document